SHARPS | Jotup

Sharps Technology’s SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.

Retrieved on:

Venerdì, Maggio 31, 2024

Patient, Glass, FDA, PFS, COC, Nephron, Growth, Acquisition, Fortune 500, Syringe

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products issues a shareholder update from Robert Hayes, the Company’s Chief Executive Officer.

Key Points:

Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation.
Sharps is negotiating additional pharma-segment purchase commitments for orders over the next three years, with shipments expected to begin by Q2 of 2025.
Earlier this week, Sharps Technology signed an enhanced Asset Purchase Agreement with Nephron Pharmaceuticals to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina.
We also signed an accompanying five-year, $200 million syringe Sales Agreement with Nephron.

Sharps Technology Signs 5-Year, $200 Million Syringe Sales Agreement and Amendment to Asset Purchase Agreement to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.

Retrieved on:

Giovedì, Maggio 30, 2024

Patient, APA, PFS, COC, Nephron, Growth, Acquisition, BlackRock, Syringe, Fine chemical

NEW YORK and WEST COLUMBIA, S.C., May 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announces the signing of a 5-year, $200 million syringe Sales Agreement (SA) with Nephron Pharmaceuticals to complement the Company’s Asset Purchase Agreement (APA) to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. The facility will be the only fully dedicated, specialized COC (cyclic olefin copolymer) prefillable syringe manufacturing plant in North America and was designed with innovative manufacturing capabilities to produce high-demand, specialty syringe systems. Product delivery is scheduled to begin late in the second quarter of 2025, with projected revenue totaling approximately $37 million for the first 12 months of sales.

Key Points:

The facility will be the only fully dedicated, specialized COC (cyclic olefin copolymer) prefillable syringe manufacturing plant in North America and was designed with innovative manufacturing capabilities to produce high-demand, specialty syringe systems.
Product delivery is scheduled to begin late in the second quarter of 2025, with projected revenue totaling approximately $37 million for the first 12 months of sales.
This transaction enables Sharps to enter the highly profitable copolymer prefillable syringe market segment, which is showing the greatest growth rate in the syringe marketplace.
With the associated $200 million Sales Agreement in place for copolymer prefillable syringes, we will substantially accelerate Sharps’ revenue growth allowing the Company to create a new level of revenue and performance,” commented Robert Hayes, Sharps Technology CEO.

Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems

Retrieved on:

Giovedì, Marzo 7, 2024

Needle, FDA, Weight loss, Syringe, Vaccine, Communication, CDMO, Safety, Administration, World Health Organization, Pharmacotherapy, Partnership, Pharmaceutical industry

The agreement, signed on March 4, 2024, lays the groundwork for further collaboration between Sharps and Roncadelle to develop and manufacture next-generation drug delivery products.

Key Points:

The agreement, signed on March 4, 2024, lays the groundwork for further collaboration between Sharps and Roncadelle to develop and manufacture next-generation drug delivery products.
“We believe that this is just the beginning of Sharps’ collaboration with Roncadelle.
“This alliance underscores our unwavering commitment to innovation and excellence, reshaping standards within the global healthcare landscape.”
Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
As part of the cooperative agreement, Sharps and Roncadelle intend to collaborate on the development of new drug delivery products.

Sharps Technology Enters Latin American Market and Receives First Orders for Securegard Disposable Smart Safety Syringes from Strategic Distribution Partner in Colombia

Retrieved on:

Mercoledì, Febbraio 21, 2024

Safety, Hospital, Pharmacotherapy, World Health Organization, Sale, Pharmacy, Patient, Pharmaceutical industry

The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region.

Key Points:

The initial product orders have been placed through a collaborative effort between Sharps and a Latin American distribution partner based in Colombia and represent a significant step towards promoting safer healthcare practices in the region.
“We are building strategic partnerships within the entire Latin American distribution network to support region-wide efforts to improve medical safety and healthcare outcomes.
The introduction of Securegard technology into Latin America can greatly enhance the overall quality level of healthcare available in that market.
For additional information on Sharps Technology and its Securegard smart safety syringes, please visit www.sharpstechnology.com .

Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

Retrieved on:

Venerdì, Febbraio 16, 2024

Diabetes, STSS, Needle, Weight loss, Infection, Syringe, Inflammation, Vaccine, CDMO, Safety, World Health Organization, Roncadelle, Disease, Partnership

Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.

Key Points:

Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
These features protect frontline healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use.
Their SafeR Retractable Safety Syringe and needles offer a passive safety system with auto-disable reuse prevention features.
Additionally, as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products of innovative, safer medical drug delivery solutions.

Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems

Retrieved on:

Giovedì, Gennaio 18, 2024

World Health Organization, Roncadelle, Weight loss, Syringe, Documentation, Needle, Administration, Communication, LOI, Safety, FDA, CDMO, Marketing, Vaccine, Pharmaceutical industry

The LOI was inked on January 16 and will be celebrated at the upcoming Pharmapack 2024 event in Paris later in the month.

Key Points:

The LOI was inked on January 16 and will be celebrated at the upcoming Pharmapack 2024 event in Paris later in the month.
“This agreement would be very beneficial for both companies.”
Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
This would open up a completely new level of service to the market,” states Ben Scheu, Senior Director of Sales for Sharps Technology.
Following the execution of a definitive sales and marketing cooperation agreement, Sharps and Roncadelle intend to collaborate on the development of new drug delivery products.

Sharps Technology Begins Manufacturing at its Hungary Facility for the Company's Innovative Syringe Products

Retrieved on:

Martedì, Dicembre 20, 2022

ISO, Medication, TCO, Syringe, Sale, Patient, Ethylene oxide, FDA, GM, Sterilization, Pharmacotherapy, Pharmaceutical industry, Borosilicate glass, European

NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.

Key Points:

NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.
The production of these specialty syringe products will ramp up over the next several months to increase supply.
Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry.
"The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary.

Sharps Technology and Nephron Pharmaceuticals Sign Distribution Agreement for its Innovative Syringe Products

Retrieved on:

Martedì, Dicembre 13, 2022

Injection, Marketing, Sale, Nephron, Regulation, Administration, Environment, Partnership, Pharmaceutical industry, Risk management

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.

Key Points:

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, is pleased to announce the signing of a distribution agreement with partner Nephron Pharmaceuticals.
“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals," commented Robert Hayes, Sharps Technology CEO.
Mr. Hayes concluded, "The distribution agreement will further accelerate the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems.

Aurora Capital Partners Completes Acquisition of Sharps Compliance Corp.

Retrieved on:

Mercoledì, Agosto 24, 2022

LOS ANGELES, Aug. 24, 2022 /PRNewswire/ -- Aurora Capital Partners ("Aurora"), a leading middle-market private equity firm, today announced that it has completed its acquisition of Sharps Compliance Corp. ("Sharps" or the "Company"), a full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous waste.

Key Points:

LOS ANGELES, Aug. 24, 2022 /PRNewswire/ -- Aurora Capital Partners ("Aurora"), a leading middle-market private equity firm, today announced that it has completed its acquisition of Sharps Compliance Corp. ("Sharps" or the "Company"), a full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous waste.
"We are excited to add Sharps' industry-leading solutions to our medical waste platform," said Andrew Wilson, Partner at Aurora.
Aurora Capital Partners is a leading Los Angeles-based private equity firm with over $4.5 billion in assets under management.
Sharps Compliance offers comprehensive solutions for the management of regulated medical waste, hazardous waste and unused medications.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sharps Compliance Corp. (Nasdaq - SMED), Infrastructure and Energy Alternatives, Inc. (Nasdaq - IEA), AutoWeb, Inc. (Nasdaq - AUTO), Zymergen Inc. (Nasdaq - ZY)

Retrieved on:

Lunedì, Luglio 25, 2022

Aurora, DNA, GLOBE, Ginkgo, IEA, NYSE, AutoWeb, Financial assistance (share purchase), Company, LLC, Brodsky, MasTec, Security (finance), Property management

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points:

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Under the terms of the agreement and plan of merger, IEA will be acquired by MasTec (NYSE MTZ) in a cash-and-stock transaction.
Aurora will commence an all-cash tender offer to acquire all of the issued and outstanding shares of Sharps for $8.75 per share.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.